Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) Bundle
Who is buying Xiangxue Pharmaceutical (300147.SZ) and why the ownership map matters: as of late 2025 institutional investors hold about 3.1% (roughly 20.5 million shares) while the largest institutional stake belongs to Guangzhou Kunlun Investment Co., Ltd. at 22.59% (data as of September 30, 2024), other notable holders include Guangzhou Luogang Water Co., Ltd. at 4.06%, Morgan Stanley at 0.60% and Barclays PLC at 0.46%, yet the general public still controls a dominant 70.2% of shares and founder Dr. Wei Li retains around 15% (approximately 420 million shares); strategic moves such as the 2020 joint venture in precision healthcare (Xiangxue's RMB 7 million investment for a 70% stake) and developments like a July 2024 court-ordered payment of 460 million yuan to Xiangxue and Guangzhou Kunlun coexist with sobering financials-52-week price range CN¥3.21-CN¥16.49, a debt-to-equity ratio near 199.1% and a first-half 2025 net loss of 234 million yuan (up 72.96% year-over-year)-all factors that shape who is buying, who is holding, and why investors might be watching Xiangxue closely.
Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) - Who Invests in Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) and Why?
Xiangxue Pharmaceutical attracts a mixed investor base: a dominant retail/public cohort, several strategic corporate stakeholders, a founder with a large personal stake, and a small but notable block of international and domestic institutional investors. Investment interest centers on the company's pharmaceutical positioning, product pipeline, and strategic moves into precision healthcare.- Institutional ownership (late 2025): ~3.1% (≈20.5 million shares)
- Largest institutional shareholder (9/30/2024): Guangzhou Kunlun Investment Co., Ltd. - 22.59%
- Other institutional stakes: Guangzhou Luogang Water Co., Ltd. - 4.06%; Morgan Stanley - 0.60%; Barclays PLC - 0.46%
- General public ownership: 70.2% (latest data)
- Founder Dr. Wei Li: ~15% (≈420 million shares)
| Holder | Reported Stake | Approx. Shares (as reported) | Rationale / Investor Type |
|---|---|---|---|
| General public | 70.2% | - | Retail investors attracted by liquidity and domestic pharma exposure |
| Guangzhou Kunlun Investment Co., Ltd. | 22.59% | - | Strategic corporate investor / control influence |
| Founder - Dr. Wei Li | ~15% | ~420,000,000 | Founder stake aligns management incentives with shareholders |
| Guangzhou Luogang Water Co., Ltd. | 4.06% | - | Corporate institutional investor |
| Morgan Stanley | 0.60% | - | Asset manager / international institutional exposure |
| Barclays PLC | 0.46% | - | International bank/investor participation |
| Other institutions (aggregate) | ~3.1% (institutional total) | ≈20,500,000 | Portfolio investors, small asset managers |
- Sector positioning: exposure to China's pharmaceutical and biotech market growth.
- Strategic initiatives: e.g., establishment of a precision healthcare management company in 2020, signaling diversification into higher-margin services.
- Governance and control dynamics: significant founder and strategic corporate holdings provide stability and direction.
- International investor interest for portfolio diversification and selective access to A-share pharma names.
Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) Institutional Ownership and Major Shareholders of Xiangxue Pharmaceutical Co.,Ltd.
Xiangxue Pharmaceutical's shareholder base combines concentrated strategic holdings and a dominant retail presence. Using the company-reported stakes and the founder's disclosed holding (Dr. Wei Li ≈15% ≈420,000,000 shares), the implied total outstanding share base is ~2,800,000,000 shares. Below are the primary shareholders and notable institutional participants as of September 30, 2024.- Largest strategic/controlling shareholder: Guangzhou Kunlun Investment Co., Ltd. - 22.59% (≈632,520,000 shares).
- Significant corporate shareholder: Guangzhou Luogang Water Co., Ltd. - 4.06% (≈113,680,000 shares).
- Founder/management: Dr. Wei Li - ~15.00% (≈420,000,000 shares).
- Retail/general public: 70.2% (≈1,965,600,000 shares), indicating heavy retail participation.
- Selected international and institutional holders: Morgan Stanley, Barclays PLC, China International Capital Corporation Hong Kong Asset Management (small single-digit basis points each).
| Shareholder | Reported Ownership (%) | Estimated Shares (based on 2,800,000,000 total) | Notes |
|---|---|---|---|
| Guangzhou Kunlun Investment Co., Ltd. | 22.59% | 632,520,000 | Largest strategic holder (as of 2024-09-30) |
| Guangzhou Luogang Water Co., Ltd. | 4.06% | 113,680,000 | Corporate investor (as of 2024-09-30) |
| Dr. Wei Li (Founder) | ~15.00% | 420,000,000 | Founder/management stake (approx.) |
| Morgan Stanley | 0.60% | 16,800,000 | Institutional position (as of 2024-09-30) |
| Barclays PLC | 0.46% | 12,880,000 | Institutional position (as of 2024-09-30) |
| China International Capital Corporation HK Asset Management Ltd. | 0.46% | 12,880,000 | Institutional position (as of 2024-09-30) |
| General public / Retail | 70.20% | 1,965,600,000 | High retail concentration |
- JV and strategic investments: In 2020, Xiangxue Pharmaceutical and Guangzhou Deyi Medical Technology Co., Ltd. formed a precision healthcare management joint venture - Xiangxue invested RMB 7 million for a 70% stake, reflecting a strategic push into precision healthcare services.
- Institutional footprint is present but modest: examples include Morgan Stanley (0.60%), Barclays (0.46%), and CICC HK AM (0.46%), reflecting limited foreign/institutional concentration versus retail and strategic domestic holders.
Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) Key Investors and Their Impact on Xiangxue Pharmaceutical Co.,Ltd.
Xiangxue Pharmaceutical's shareholder structure and recent events shape both market perception and operational flexibility. Major institutional stakes, the founder's sizeable holding, a dominant retail base, and legal exposures together influence liquidity, corporate governance dynamics, and strategic options.- Largest institutional investor: Guangzhou Kunlun Investment Co., Ltd. - 22.59% (as of Sept 30, 2024).
- Significant industrial/strategic holder: Guangzhou Luogang Water Co., Ltd. - 4.06% (as of Sept 30, 2024).
- Founder stake: Dr. Wei Li holds ~15% (~420 million shares), aligning management incentives with shareholders.
- Retail/General public: 70.2% of shares held by the public, indicating heavy retail participation and potential for price volatility from sentiment-driven flows.
- Legal/financial stress: In July 2024, Xiangxue Pharmaceutical and major shareholder Guangzhou Kunlun were subject to a court-ordered payment of RMB 460 million.
- Strategic investments: In 2020 Xiangxue Pharmaceutical invested RMB 7 million for a 70% stake in a precision healthcare management JV with Guangzhou Deyi Medical Technology Co., Ltd.
| Holder | Reported % (Sept 30, 2024) | Estimated Shares (approx.) | Notes / Impact |
|---|---|---|---|
| Guangzhou Kunlun Investment Co., Ltd. | 22.59% | ~632.5 million | Largest institutional influence; party to July 2024 RMB 460M court-ordered payment |
| Dr. Wei Li (Founder) | ~15.00% | ~420.0 million | Significant insider alignment; estimated total shares base ≈2.8 billion (420m/15%) |
| Guangzhou Luogang Water Co., Ltd. | 4.06% | ~113.7 million | Strategic/commercial investor with modest stake |
| General Public (retail) | 70.20% | ~1,965.6 million | High retail concentration; amplifies volatility and retail-driven trading patterns |
| Joint Venture (2020 investment) | 70% of JV equity | RMB 7 million capital contribution | Positions Xiangxue in precision healthcare management; small cash outlay with strategic intent |
- Governance and control: Guangzhou Kunlun's 22.59% stake gives it substantial sway in board-level decisions and in negotiations with management; founder's ~15% further concentrates influence with management alignment.
- Liquidity and volatility: Heavy retail ownership (70.2%) tends to increase short-term trading volume and may amplify reactions to news, earnings, or legal developments.
- Legal risk and balance sheet pressure: The July 2024 court-ordered payment of RMB 460M involving the company and Guangzhou Kunlun poses potential cash-flow or financing stress, could affect credit terms or force asset/liability adjustments.
- Strategic optionality via JVs: The 2020 JV (RMB 7M for 70% stake) demonstrates targeted, low-capital strategic moves into precision healthcare that may expand future revenue streams without large near-term cash burden.
- Activism and takeover dynamics: With institutional blocks (Kunlun 22.59%) and an influential founder stake, potential activist moves or control contests would center around these stakeholders rather than dispersed retail holders.
Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) - Market Impact and Investor Sentiment
As of late 2025, Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) exhibits pronounced market volatility and a mixed investor sentiment profile driven by financial distress, retail ownership concentration, legal exposures and selected strategic initiatives.- Share-price volatility: 52-week low CN¥3.21 vs high CN¥16.49, signaling pronounced trading swings and sentiment sensitivity.
- Leverage concerns: debt-to-equity ratio of 199.1% - a material balance-sheet strain that raises refinancing and interest-risk anxieties.
- Profitability shock: H1 2025 net loss of CN¥234 million, up 72.96% year-over-year, pressuring earnings expectations and valuation.
- Retail-dominated cap structure: general public holds 70.2% of shares, amplifying momentum-driven moves and sentiment-driven volatility.
- Legal and counterparty risk: July 2024 court-ordered payment of CN¥460 million involving the company and major shareholder Guangzhou Kunlun Investment Co., Ltd., adding near-term cash outflow and reputational stress.
- Strategic offsets: prior strategic moves (e.g., 2020 joint venture in precision healthcare management) provide optionality that some investors view as a positive long-term catalyst.
| Metric | Value |
|---|---|
| 52-week range | CN¥3.21 - CN¥16.49 |
| Debt-to-Equity Ratio | 199.1% |
| H1 2025 Net Income | Loss of CN¥234 million (▲72.96% YoY) |
| Retail/Public Ownership | 70.2% |
| Court-ordered Payment (Jul 2024) | CN¥460 million (company & major shareholder) |
| Notable Strategic Initiative | 2020 joint venture in precision healthcare management |
- Retail/speculative traders: dominate volume due to 70.2% public float - responsive to news, price momentum and short-term catalysts.
- Risk-tolerant value seekers: attracted by depressed multiples after losses and low share-price levels; view JV and asset base as recovery upside.
- Credit-sensitive institutional investors: deterred by 199.1% leverage and recurring losses; require evidence of deleveraging and consistent cash flow before reengaging.
- Event-driven funds and activists: monitor legal rulings (e.g., CN¥460m payment) and governance moves tied to major shareholder actions for arbitrage or restructuring plays.
- Higher perceived risk → wider bid-ask spreads and potential premium demanded by lenders/investors.
- Earnings deterioration and leverage → increased probability of equity dilution or asset disposals to shore up liquidity.
- Retail concentration → sharper rebounds or drawdowns on company-specific news versus fundamentals-driven peers.
Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.